Rapid Micro Biosystems (RPID) AI Stock Analysis

• Market Cap: $156.92M
• Dividend Yield: N/A
• Average Volume (3M): 89.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 28.36%
• EPS Growth: 14.87%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.26
• Shares Outstanding: 39,332,172
• 10 Day Avg. Volume: 92,137
• 30 Day Avg. Volume: 89,028
• PEG Ratio: 0.04
• Price to Book (P/B): 0.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: 0.27
• Enterprise Value/Gross Profit: 8.04
• Enterprise Value/Ebitda: -0.15
• 1Y Price Target: $8.00
• Price Target Upside: 123.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: $3.50 ▼(-2.23%Downside)

The overall score reflects the company's strong technical performance and positive recent earnings call, offset by financial challenges such as negative profitability and cash flow issues. While the stock is technically strong, significant operational and financial improvements are needed for a higher score.

Positive Factors

Market Acceptance

RPID's system has 164 installations and is used by 70% of the top 20 biopharmas and Lonza, validating its acceptance and effectiveness in the market.

Product Adoption

Rapid Micro Bio's Microbial Growth Direct System is changing the paradigm in biological manufacturing quality control by being more accurate and providing digital results faster than traditional methods.

Revenue Growth

The company is gaining wide adoption in the biopharmaceutical industry, with a 28% revenue growth from 2022-2024, leading to increased top-line visibility and improving margins.

Negative Factors

Dependence on Key Customers

The Q3 was driven by a multi-system Growth Direct instrument order from an existing top 20 global pharma customer, raising questions about dependency on a few large clients for revenue.

Revenue Expectations

Although Q3 revs of $7.6M hit a record-high for the company, there may be concerns about sustaining this level of revenue growth.

Rapid Micro Biosystems Business Overview & Revenue Model

Company Description

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

How the Company Makes Money

Rapid Micro Biosystems generates revenue primarily through the sale of its automated microbial detection systems and related consumables. The company offers a range of products designed to improve the efficiency and effectiveness of microbial contamination testing in manufacturing environments. Revenue streams include the initial sale of detection instruments, ongoing sales of consumable testing materials required for regular system operation, and service agreements for maintenance and support. Additionally, the company may engage in strategic partnerships with pharmaceutical and biotechnology firms to enhance its market reach and leverage collaborative opportunities.

Rapid Micro Biosystems Financial Statement Overview

Summary

Rapid Micro Biosystems shows strong revenue growth but struggles with profitability and cash flow. A strong equity base is offset by negative margins and cash flow challenges, impacting financial health.

Income Statement

The company has shown consistent revenue growth, with a significant revenue growth rate of 9.8% in the TTM (Trailing-Twelve-Months). However, profitability metrics are concerning, with negative gross profit margin of 12.1% and net profit margin of -151.2% in the TTM. The EBIT and EBITDA margins are also negative, indicating operational challenges and high operating expenses.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 76.6% in the TTM, showcasing financial stability. However, the debt-to-equity ratio is low at 0.09, indicating limited leverage, which can be both a strength and a limitation for growth. However, the return on equity is negative due to persistent net losses, indicating inefficiencies in generating returns from shareholder equity.

Cash Flow

The company faces cash flow challenges with negative operating and free cash flows. The operating cash flow to net income ratio is 0.84, which suggests that cash generation remains a challenge despite net income levels. Additionally, the free cash flow growth rate is negative, indicating a worsening free cash flow situation over time.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.64M	28.05M	22.52M	17.13M	23.23M	16.08M
Gross Profit	3.59M	-109.00K	-5.49M	-8.54M	-7.74M	-8.07M
EBITDA	-44.33M	-46.56M	-53.76M	-60.38M	-45.80M	-32.00M
Net Income	-44.83M	-46.89M	-52.47M	-60.81M	-73.52M	-37.08M
Balance Sheet
Total Assets	85.43M	98.17M	143.45M	190.65M	241.17M	70.00M
Cash, Cash Equivalents and Short-Term Investments	41.67M	50.73M	92.05M	108.65M	193.50M	45.08M
Total Debt	5.88M	6.17M	7.35M	7.97M	400.00K	24.81M
Total Liabilities	19.94M	22.82M	25.46M	26.48M	20.19M	45.18M
Stockholders Equity	65.49M	75.35M	117.99M	164.17M	220.98M	24.82M
Cash Flow
Free Cash Flow	-38.79M	-45.52M	-46.93M	-65.29M	-58.18M	-31.69M
Operating Cash Flow	-37.69M	-44.15M	-45.08M	-58.55M	-54.96M	-31.00M
Investing Cash Flow	33.82M	36.66M	42.15M	-93.47M	-13.29M	-15.67M
Financing Cash Flow	424.00K	203.00K	149.00K	693.00K	216.75M	64.23M

Rapid Micro Biosystems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Positive. The current price of 3.58 is above the 20-day moving average (MA) of 3.49, above the 50-day MA of 3.03, and above the 200-day MA of 1.95, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 57.31 is Neutral, neither overbought nor oversold. The STOCH value of 66.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPID.

Rapid Micro Biosystems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	74 Outperform	$93.89M	12.18	5.00%	―	0.29%	-22.13%
SRTS	70 Outperform	$79.92M	44.22	3.46%	―	24.75%	-61.29%
MASS	66 Neutral	$241.35M	―	-44.97%	―	21.06%	-99.70%
RPID	60 Neutral	$156.92M	―	-52.30%	―	28.36%	14.87%
ICAD	60 Neutral	$105.21M	―	-16.53%	―	-4.15%	3.49%
XTNT	54 Neutral	$87.63M	―	-26.20%	―	20.81%	-498.66%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%

Rapid Micro Biosystems Corporate Events

Rapid Micro Biosystems CEO Diagnosed with Lymphoma

On June 17, 2025, Robert Spignesi, CEO of Rapid Micro Biosystems, announced his diagnosis with a treatable form of Lymphoma. Despite the diagnosis and ongoing treatment, Spignesi plans to continue leading the company with limited in-person presence, expressing confidence in the company’s ability to maintain its performance and thanking the team for their support.

The most recent analyst rating on (RPID) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.

Rapid Micro Biosystems Board Resignation and Elections

On May 22, 2025, Jeffrey Schwartz resigned from the board of directors of Rapid Micro Biosystems, where he served since April 2018, without any disagreements with the company. During the company’s annual meeting on the same day, stockholders elected Dafni Bika and Inese Lowenstein as Class I Directors and ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025.

The most recent analyst rating on (RPID) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.